ID   VMM15
AC   CVCL_A736
DR   ATCC; CRL-3227
DR   cancercelllines; CVCL_A736
DR   GEO; GSM1672070
DR   GEO; GSM1672077
DR   GEO; GSM1672090
DR   GEO; GSM1672106
DR   GEO; GSM1672122
DR   GEO; GSM1672127
DR   Wikidata; Q54993234
RX   PubMed=10752474;
RX   PubMed=14871852;
RX   PubMed=20856146;
RX   PubMed=21654344;
RX   PubMed=26405815;
RX   PubMed=26673621;
CC   Population: Caucasian.
CC   HLA typing: A*01,25; B*08,18 (PubMed=10752474).
CC   Sequence variation: Mutation; HGNC; HGNC:1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=26405815).
CC   Omics: Deep exome analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Derived from site: Metastatic; Lymph node; UBERON=UBERON_0000029.
ST   Source(s): ATCC=CRL-3227
ST   Amelogenin: X
ST   CSF1PO: 10
ST   D13S317: 12
ST   D16S539: 12
ST   D5S818: 9,15
ST   D7S820: 10,12
ST   TH01: 6
ST   TPOX: 8
ST   vWA: 17,18
DI   NCIt; C3224; Melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   39Y
CA   Cancer cell line
DT   Created: 06-06-12; Last updated: 19-12-24; Version: 19
//
RX   PubMed=10752474; DOI=10.1007/s002620050015; PMCID=PMC11037162;
RA   Slingluff C.L. Jr., Colella T.A., Thompson L., Graham D.D.,
RA   Skipper J.C.A., Caldwell J., Brinckerhoff L., Kittlesen D.J.,
RA   Deacon D.H., Oei C., Harthun N.L., Huczko E.L., Hunt D.F.,
RA   Darrow T.L., Engelhard V.H.;
RT   "Melanomas with concordant loss of multiple melanocytic
RT   differentiation proteins: immune escape that may be overcome by
RT   targeting unique or undefined antigens.";
RL   Cancer Immunol. Immunother. 48:661-672(2000).
//
RX   PubMed=14871852; DOI=10.1158/0008-5472.CAN-03-2209;
RA   Hogan K.T., Coppola M.A., Gatlin C.L., Thompson L.W., Shabanowitz J.,
RA   Hunt D.F., Engelhard V.H., Ross M.M., Slingluff C.L. Jr.;
RT   "Identification of novel and widely expressed cancer/testis gene
RT   isoforms that elicit spontaneous cytotoxic T-lymphocyte reactivity to
RT   melanoma.";
RL   Cancer Res. 64:1157-1163(2004).
//
RX   PubMed=20856146; DOI=10.1097/CMR.0b013e32833fafb4; PMCID=PMC3229868;
RA   Mikesh L.M., Kumar M., Erdag G., Hogan K.T., Molhoek K.R., Mayo M.W.,
RA   Slingluff C.L. Jr.;
RT   "Evaluation of molecular markers of mesenchymal phenotype in
RT   melanoma.";
RL   Melanoma Res. 20:485-495(2010).
//
RX   PubMed=21654344; DOI=10.1097/CMR.0b013e328343a1d6; PMCID=PMC3131461;
RA   Molhoek K.R., Shada A.L., Smolkin M., Chowbina S., Papin J.,
RA   Brautigan D.L., Slingluff C.L. Jr.;
RT   "Comprehensive analysis of receptor tyrosine kinase activation in
RT   human melanomas reveals autocrine signaling through IGF-1R.";
RL   Melanoma Res. 21:274-284(2011).
//
RX   PubMed=26405815; DOI=10.1371/journal.pone.0138210; PMCID=PMC4583389;
RA   Capaldo B.J., Roller D.G., Axelrod M.J., Koeppel A.F., Petricoin E.F. 3rd,
RA   Slingluff C.L. Jr., Weber M.J., Mackey A.J., Gioeli D., Bekiranov S.;
RT   "Systems analysis of adaptive responses to MAP kinase pathway blockade
RT   in BRAF mutant melanoma.";
RL   PLoS ONE 10:E0138210-E0138210(2015).
//
RX   PubMed=26673621; DOI=10.18632/oncotarget.6548; PMCID=PMC4823068;
RA   Roller D.G., Capaldo B.J., Bekiranov S., Mackey A.J., Conaway M.R.,
RA   Petricoin E.F. 3rd, Gioeli D., Weber M.J.;
RT   "Combinatorial drug screening and molecular profiling reveal diverse
RT   mechanisms of intrinsic and adaptive resistance to BRAF inhibition in
RT   V600E BRAF mutant melanomas.";
RL   Oncotarget 7:2734-2753(2016).
//